tradingkey.logo
tradingkey.logo
検索

Adagene Inc

ADAG
ウォッチリストに追加
1.710USD
-0.290-14.50%
終値 11-13 16:00(ET)
112.98M時価総額
損失額直近12ヶ月PER

Adagene Incについて 企業名

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Adagene Inc プロフィール

企業コードADAG
会社名Adagene Inc
上場日Feb 09, 2021
最高経営責任者「CEO」Luo (Peter)
従業員数138
証券種類Depository Receipt
決算期末Feb 09
本社所在地4F, Building C14, No. 218, Xinghu Street
都市SUZHOU
証券取引所NASDAQ OMX - NASDAQ BASIC
国China
郵便番号- -
電話番号8651287773632
ウェブサイトhttps://www.adagene.com/
企業コードADAG
上場日Feb 09, 2021
最高経営責任者「CEO」Luo (Peter)

Adagene Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Ms. Ami Knoefler
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Dr. Zha Jiping, Ph.D.
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Mr. Cheung (Yiu Leung) Andy
Mr. Cheung (Yiu Leung) Andy
Independent Director
Independent Director
--
--
Ms. Yuwen Liu
Ms. Yuwen Liu
Independent Director
Independent Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.64M
+1.23%
Ms. Ami Knoefler
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Dr. Zha Jiping, Ph.D.
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--

よくある質問

Adagene Incの上位5名の株主は誰ですか?

Adagene Incの上位5名の株主は以下のとおりです。Dr. Peter (Peizhi) Luo, Ph.D.

Adagene Inc(ADAG)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Adagene Incの株式を保有している機関は38社あり、保有株式の総市場価値は約13.55Mで、全体の20.51%を占めています。2025Q4と比較して、機関の持ち株は-2119805.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。